Compara mètodes

	Assaig clínic multicèntric de fase II	Assaig Clínic de Fase I Multicèntric
Camp	Epidemiologia	Epidemiologia
Família	Process / pipeline	Process / pipeline
Any d'origen	1970s–1980s (formalized in regulatory guidance; Simon two-stage design 1989)	1970s–1980s (formalized in FDA Phase I guidance 1977; ICH E6 GCP 1996)
Autor original	Established through ICH and FDA regulatory frameworks; Simon two-stage design formalized by Richard Simon (1989)	Established through FDA regulatory guidance and ICH harmonization frameworks
Tipus	Interventional clinical trial design	Interventional clinical study design
Font seminal	International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). (2009). ICH Harmonised Tripartite Guideline: General Considerations for Clinical Studies E8(R1). ICH.	International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). (2016). ICH Harmonised Guideline: Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice E6(R2). ICH.
Àlies	multi-site phase II trial, phase 2 multicenter study, multicenter Phase IIA/IIB trial, multisite efficacy trial	multisite Phase I trial, multi-institutional Phase I study, Phase I dose-escalation multicenter study, first-in-human multicenter trial
Relacionats	6	6
Resum	A multicenter phase II clinical trial is an interventional study conducted at two or more independent clinical sites to evaluate the preliminary efficacy and safety of a new treatment in a defined patient population, following demonstrated tolerability in phase I. By pooling patients across sites, the design achieves the sample sizes needed to estimate response rates and identify promising signals before committing to the larger investment of a phase III confirmatory trial.	A multicenter Phase I clinical trial is the first systematic administration of an investigational agent to humans, conducted simultaneously across two or more clinical sites. Its primary objectives are to characterize the safety and tolerability profile of the intervention, determine the maximum tolerated dose (MTD), and describe pharmacokinetic and pharmacodynamic behavior. Distributing enrollment across sites increases participant accrual speed and enhances the generalizability of early-phase safety data.